These findings also provided proof that inhibiting TLR4/NF-κB pathway by natural compounds was an effective chemopreventive strategy for breast cancer, and AT-I appeared to have potential value as a novel candidate for breast cancer treatment. This evidence concerns the gene NFKB1 and breast cancer.